A study of HPV 1, 2 and 4 antibody prevalence in patients presenting for treatment with cutaneous warts to general practitioners in N. Ireland

Steele, K; Shirodaria, P. V.; Pfister, Herbert; Pollock, Bradley H; Fuchs, Pawel G.; Merrett, J. D.; Irwin, W. G.; Simpson, David

doi:10.1017/s0950268800029411

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Common warts are most frequently associated with HPV types 1, 2, and 7, plantar warts with types 1 and 2, and flat warts with types 3 and 10. Other higher-risk HPV types are oncogenic and are a principal cause of cervical cancer [4, 5]. Differentiation of HPV types is based on the nucleotide sequence of the L1 major protein [6].…”

Section: Introductionmentioning

confidence: 99%

Identification of Immunodominant T-lymphocyte Epitope Peptides in HPV 1, 2 and 3 L1 Protein for Novel Cutaneous Wart Vaccine

Toh

Wang

Chung

2021

Preprint

View full text Add to dashboard Cite

Background: Common warts and flat warts are caused by the human papillomavirus (HPV). Peak incidence of wart infection occurs in schoolchildren aged 12-16, where prevalence can be as high as 20%. Traditional treatments aimed at destruction of wart tissue have low clearance rates and high recurrence rates. Occasional reports have even shown warts becoming malignant and progressing into verrucous carcinoma. Current licensed HPV vaccines largely target higher-risk oncogenic HPV types, but do not provide coverage of low-risk types associated with warts. To date, little attention has been given to the development of effective, anti-viral wart treatments. Objective: This study aims to identify immunodominant T-lymphocyte epitopes from the L1 major capsid protein of HPV 1, 2 and 3, a foundational step in bioengineering a peptide-based vaccine for warts. Methods: Cytotoxic T-cell and helper T-cell epitopes were predicted using an array of immunoinformatic tools against a reference panel of frequently observed MHC-I and MHC-II alleles. Predicted peptides were ranked based on IC50 and IFN-γ Inducer Scores, respectively, and top performing epitopes were synthesized and subjected to in vitro screening by IFN-γ enzyme-linked immunosorbent spot assay (ELISpot). Independent trials were conducted using PBMCs of healthy volunteers. Final chosen peptides were fused with flexible GS linkers in silico to design a novel polypeptide vaccine. Results: Seven immunodominant peptides screened from 44 predicted peptides were included in the vaccine design, selected to elicit specific immune responses across MHC class I and class II, and across HPV types. Evaluation of the vaccine′s properties suggest that the vaccine is stable, non-allergenic, and provides near complete global population coverage (>99%). Solubility prediction and rare codon analysis indicate that the DNA sequence encoding the vaccine is suitable for high level expression in Escherichia coli. Conclusions: In sum, this study demonstrates the potential and lays the framework for the development of a peptide-based vaccine against warts.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of Immunodominant T-lymphocyte Epitope Peptides in HPV 1, 2 and 3 L1 Protein for Novel Cutaneous Wart Vaccine

Toh

Wang

Chung

2021

Preprint

View full text Add to dashboard Cite

show abstract

Incidence of antibodies to human papillomavirus type 1 in patients with cutaneous and mucosal papillomas

Viac

Chomel

Chardonnet

et al. 1990

Journal of Medical Virology

View full text Add to dashboard Cite

A study of antibodies to human papillomavirus (HPV) 1 is reported in a series of sera from 126 patients with papilloma lesions of different clinical types (verruca plantaris, vulgaris, plana, condyloma acuminata, laryngeal papilloma) using a sensitive solid-phase enzyme-linked immunosorbent assay (ELISA). Our findings showed a significant prevalence of specific HPV 1 IgG antibodies in patients with plantar warts (65%). This incidence was considerably lower in patients with other papilloma lesions, in which positive sera may reflect a past infection with HPV 1. The ELISA test was evaluated as nearly 100 times more sensitive than the indirect immunofluorescence test, and IgG titers to HPV 1 in patients' sera were usually low. Serum samples taken at different times during the course of HPV infection in a few patients with refractory lesions did not show any significant change in their antibody titer.

show abstract

Antibody responses to human papillomavirus type‐16 infections

Cason

Best

1991

Reviews in Medical Virology

View full text Add to dashboard Cite

A study of HPV 1, 2 and 4 antibody prevalence in patients presenting for treatment with cutaneous warts to general practitioners in N. Ireland

Cited by 5 publications

References 13 publications

Identification of Immunodominant T-lymphocyte Epitope Peptides in HPV 1, 2 and 3 L1 Protein for Novel Cutaneous Wart Vaccine

Identification of Immunodominant T-lymphocyte Epitope Peptides in HPV 1, 2 and 3 L1 Protein for Novel Cutaneous Wart Vaccine

Incidence of antibodies to human papillomavirus type 1 in patients with cutaneous and mucosal papillomas

Antibody responses to human papillomavirus type‐16 infections

Contact Info

Product

Resources

About